Longitude Capital is a healthcare-focused venture capital firm investing across biotechnology, medical technology, and health solutions with a concentration on oncology, neurodegenerative diseases, aging-related treatments, and innovative care delivery models. The firm deploys capital from seed through growth stages, with particular expertise in complex transactions including corporate spinouts, recapitalizations, and public market opportunities. Its investment thesis centers on improving clinical outcomes, enhancing patient quality of life, and driving efficiency gains in healthcare delivery, supported by an in-house research team and sector specialists. Longitude Capital's portfolio spans ...
Asset class
Impact theme
Investment geographies
Longitude Venture Partners IV is a venture capital fund that closed at $585 million in committed capital, representing the fourth and largest fund in Longitude Capital's portfolio. The fund invests across early-stage and growth-stage healthcare companies in North America, targeting the biotechnology, medical technology, and health solutions sectors with emphasis on aging populations. LVP4 pursues an impact thesis centered on improving clinical outcomes, enhancing patient quality of life, and increasing healthcare delivery efficiency, with particular attention to smart, data-collecting implantable devices. The fund maintains Longitude Capital's core competency in backing transformative healthcare solutions that demonstrate measurable improvements in patient care and healthcare system efficiency.
| Limited Partner |
|---|
 The California Wellness Foundation Foundation or endowment |
